See today's BioWorld
To read the full article sign up for free or sign in.

Disc over the moon as FDA urges Apollo bid with bitopertin in EPP

Nov. 4, 2024
By Randy Osborne
Disc Medicine Inc. found itself after an end-of-phase II meeting with the U.S. FDA in what Wainwright analyst Douglas Tsao called a “best-case scenario” regarding the path forward for bitopertin in erythropoietic protoporphyria (EPP).
BioWorld Regulatory Dermatologic Hematologic Small molecule FDA